Text Size

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

This study has been terminated.
(Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized)
Sponsor:
Information provided by (Responsible Party):
Shire Development LLC
ClinicalTrials.gov Identifier:
NCT01760889
First received: January 2, 2013
Last updated: May 3, 2013
Last verified: May 2013
History of Changes
  Purpose

The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.


Condition Intervention Phase
Schizophrenia
 Drug: SPD489 low dose range (40mg, 80mg, and 100mg)
Drug: SPD489 high dose range (120mg, 140mg and 160mg)
Drug: Placebo
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 26-week, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 Low Dose Range (40mg, 80mg, 100mg) and High Dose Range (120mg, 140mg, 160mg) as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Further study details as provided by Shire Development LLC:

Primary Outcome Measures:
  • Change from Baseline in Negative Symptom Assessment (NSA-16) Total Score at 26 Weeks [ Time Frame: Baseline and 26 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from Baseline in the Personal and Social Performance (PSP) Scale Score at 26 Weeks [ Time Frame: Baseline and 26 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in Simpson Angus Scale (SAS) Total Score at 26 Weeks [ Time Frame: Baseline and 26 weeks ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 26 Weeks [ Time Frame: Baseline and 26 weeks ] [ Designated as safety issue: Yes ]
  • Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 26 Weeks [ Time Frame: Baseline and 26 weeks ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 26 Weeks [ Time Frame: Baseline and 26 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 26 Weeks [ Time Frame: Baseline and 26 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Social Functioning Scale (SFS) at 26 Weeks [ Time Frame: Baseline and 26 weeks ] [ Designated as safety issue: No ]
  • Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale [ Time Frame: Baseline and week 26 ] [ Designated as safety issue: No ]
  • Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: No ]
  • Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 26 Weeks [ Time Frame: Baseline and 26 weeks ] [ Designated as safety issue: Yes ]
  • Change from Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 26 Weeks [ Time Frame: Baseline and 26 weeks ] [ Designated as safety issue: Yes ]
  • Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Up to 26 weeks ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 26 Weeks [ Time Frame: Baseline and 26 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 1
Study Start Date: February 2013
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SPD489 Low Dose Range Drug: SPD489 low dose range (40mg, 80mg, and 100mg)

Capsule, dose titration,

  • 40 mg capsule once-daily for 1 week; then
  • 80 mg capsule once-daily for 4 weeks; then,
  • 100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;
  • if able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks
Other Name: lisdexamfetamine dimesylate, LDX, Vyvanse
Experimental: SPD489 High Dose Range Drug: SPD489 high dose range (120mg, 140mg and 160mg)

Capsule, dose titration,

  • 40 mg capsule once-daily for 1 week; then
  • 80 mg capsule once daily for 1 week; then
  • 120 mg capsule once-daily for 1 week, then,
  • 140 mg capsule once-daily for 2 weeks, then
  • 160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;
  • if able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks
Other Name: lisdexamfetamine dimesylate, LDX, Vyvanse
Placebo Comparator: Placebo Drug: Placebo
One capsule a day for 26 weeks

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • - 18 to 65 years of age
  • Has a reliable informant (eg, family member, social worker, caseworker, or nurse that spends >4 hours/week with the subject)
  • Fixed home/place of residence and can be reached by telephone
  • On a stable dose of antipsychotic medications
  • Able to swallow capsules

Exclusion Criteria:

  • Taking lithium, carbamazepine, lamotrigine, gabapentin, cholinesterase inhibitors, modafinil, or other stimulants such as methylphenidate and other amphetamine products
  • Treated with clozapine in past 30 days
  • Lifetime history of stimulant, cocaine, or amphetamine abuse or dependence
  • History of seizures (other than infantile febrile seizures), any tic disorder, or current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions
  • Uncontrolled hypertension
  • History of thyroid disorder that has not been stabilized on thyroid medication
  • Glaucoma
  • Pregnant or nursing
  • Subject has received an investigational product or participated in a clinical study within 30 days
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01760889

Locations
United States, Florida
Galiz Research
Miami Springs, Florida, United States, 33166
United States, Missouri
Psychiatric Care and Research Center
O'Fallon, Missouri, United States, 63368
St. Charles Psychiatric Associates
St. Charles, Missouri, United States, 63304
United States, Pennsylvania
CRI Lifetree
Philadelphia, Pennsylvania, United States, 19139
Sponsors and Collaborators
Shire Development LLC
Investigators
Principal Investigator: Stephen R. Marder, MD Desert Pacific Mental Illness Research Education and Clinical Center Semel Institute for Neuroscience at UCLA
  More Information

No publications provided

Responsible Party: Shire Development LLC
ClinicalTrials.gov Identifier: NCT01760889     History of Changes
Other Study ID Numbers: SPD489-335, 2012-003919-57
Study First Received: January 2, 2013
Last Updated: May 3, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Antipsychotic Agents
Dextroamphetamine
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
 Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Central Nervous System Stimulants

ClinicalTrials.gov processed this record on May 21, 2013